Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb : PsiOxus to Advance Cancer Therapy Assessment

04/07/2021 | 05:02am EDT


© MT Newswires 2021
All news about BRISTOL-MYERS SQUIBB COMPANY
05/07INSIDER TRENDS : 90-Day Insider Buying Trend at Bristol-Myers Squibb Interrupted..
MT
05/07INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Bristol-Myer..
MT
05/07EVOTEC  : launches 'beLAB1407' to accelerate translational research from the UK'..
AQ
05/06BRISTOL MYERS SQUIBB CO  : Submission of Matters to a Vote of Security Holders, ..
AQ
05/06GLAXOSMITHKLINE  : GSK Appoints Charles Bancroft As Member Of Nominations & Corp..
RE
05/06DARWINHEALTH  : Announces a Research Collaboration with Bristol Myers Squibb for..
PR
05/05BRISTOL MYERS SQUIBB  : to Take Part in the 2021 Bank of America Securities Heal..
BU
05/04BRISTOL MYERS SQUIBB CO  : Change in Directors or Principal Officers, Amendments..
AQ
05/03BRISTOL MYERS SQUIBB  : Presents New Clinical and Real-World Data on Mavacamten ..
BU
04/30BRISTOL MYERS SQUIBB  : Application for Opdivo Accepted by FDA for Priority Revi..
MT
More news
Financials (USD)
Sales 2021 46 094 M - -
Net income 2021 7 190 M - -
Net Debt 2021 26 819 M - -
P/E ratio 2021 20,2x
Yield 2021 3,02%
Capitalization 144 B 144 B -
EV / Sales 2021 3,70x
EV / Sales 2022 3,35x
Nbr of Employees 30 250
Free-Float 76,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 75,46 $
Last Close Price 64,44 $
Spread / Highest target 39,7%
Spread / Average Target 17,1%
Spread / Lowest Target -3,79%
EPS Revisions
Managers and Directors
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY3.92%143 884
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
PFIZER, INC.6.47%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539